TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS

Slides:



Advertisements
Similar presentations
Angela Singh, PharmD Assistant Professor of Pharmacy FAMU COPPS IPPE I
Advertisements

Drugs as Medicines Coach Graner Health Class Notes.
National Prescription Drug Threat Assessment 2009 National Drug Intelligence Center Drug Enforcement Administration.
World Health Organization
Pharmacology Application in Athletic Training Michelle Odai, MS, LAT, ATC, CSCS Florida International University.
Prepared by Long Island Quality Associates, Inc. ISO 9001:2000 Documentation Requirements Based on ISO/TC 176/SC 2 March 2001.
VINOD P. SHAH, PH.D. SENIOR RESEARCH SCIENTIST OFFICE OF PHARMACEUTICAL SCIENCE CENTER FOR DRUG EVALUATION AND RESEARCH FOOD AND DRUG ADMINISTRATION Pharmacy.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Pharmaceutical Drug Abuse Counterfeit Drugs. Current State of Affairs National drug prevalence studies indicate a sharp increase in prescription drug.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
309: Prescription Drug Abuse. The Pennsylvania Child Welfare Resource Center Learning Objectives Participants will be able to: –Associate the history.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
STIMULANTS. What Are They? Defintion: Stimulants are a class of drugs that elevate mood, increase feelings of well-being, and increase energy and alertness.
Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B
Pain Management And Prescribing Controlled Drugs Timothy J. Benedict, RPh Assistant Executive Director Ohio State Board of Pharmacy
Drugs as Medicines Coach Graner Health Class Notes.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 1 A Brief History.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation Fundamentals of Pharmacology for Veterinary Technicians 1 Submitted by Callie Parr.
Government and Industry Response to Rx Abuse Robert Bianchi Prescription Drug Research Center - Chicago, IL Atlanta GA - April 7, 2015.
Slide 1 Review of the Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health September 8, 2015.
OR “READ THE FINE PRINT PLEASE!”
Demonstrably Difficult to Compound Drug Products Kathleen Anderson, Pharm. D. Division of Prescription Drug Compliance and Surveillance Office of Compliance.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Compounding Kenneth Schell Pharm. D President, CA State Board of Pharmacy.
Basic Nursing: Foundations of Skills & Concepts Chapter 9
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
Necessary Knowledge for Medical Assistants  Types of Medications  How they are packaged  Routes of Administration  Steps to administering oral medications.
Investigational Devices and Humanitarian Use Devices June 2007.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
미국의 마약류 관리제도 - FDA 와 NIDA 의 조직 및 업무 현황 의약품평가부 이선희.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert P. Bianchi PDRC/NMS Labs Drug Delivery Partnership February 8, 2013 San Diego, CA.
DRUGS Prescription, OTC and Supplements. Drugs A drug is a substance other than food that changes the way the body or mind functions. People use drugs.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert Bianchi – Prescription Drug Research Center, LLC American Pain Society Meeting – Baltimore, MD.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Drug Enforcement Administration Greater Kansas City Chapter American Society for Pain Management Nursing October 24, 2015 Judy R. Williams Group Supervisor.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS
Bob Bianchi Prescription Drug Research Center Category 1 Focus Group Meeting Washington DC November,
In vitro - In vivo Correlation
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 3 Drug Regulation, Development, Names, and Information.
Incidental Medical Services (IMS) Department of
BSB Biomanufacturing CHAPTER 11 GMP – Pharmaceutical Water
Legal and Illegal Drugs
Drug Formulary Commission
Wireless Access SSID: cwag2017
Opioids, Synthetics and Cannabis……. OH MY!
- Pharmaceutical Equivalence Study
5th Annual Empowering Local Leadership Conference
Drugs and Prescription Records
Drugs and Prescription Records
Biopharmaceutics of modified release drug products
WHO Technical Report Series, No. 953, 2009
Medications!!!.
H A C C P HAZARD ANALYSIS CRITICAL CONTROL POINTS 1 December 2018
Chapter 35 Basic Pharmacology.
Can Novel Delivery Systems Deter Rx Drug Abuse?
Government and Industry Response to the US Opioid Epidemic
Ethical Considerations for Pediatric Clinical Investigations
Ch 18: Pharmacy.
Compounded Drugs and Lack of Premarket FDA-Approval
Understanding Drug Labels
Regulatory Perspective of the Use of EHRs in RCTs
Multiple Check System Order entry, bar coding, and technological checks Best method: manual redundancy system and the “5 rights and 3 checks” method.
Guideline for Elemental Impurities ICH Q3D(R)
Presentation transcript:

TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Abuse Deterrent Formulation Science September 30, 2013 Bethesda MD TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert P. Bianchi Prescription Drug Research Center – Chicago, IL

BACKGROUND Prescription drug abuse is the fastest rising category of drug abuse in the US, second only to cannabis and synthetic cannabinoids (ONDCP – Drug Control Strategy 2011). Prescription drug abusers increased to 16.7 million in 2012 from 14.7 in 2011 (NSDUH 2012) According to DEA, 17 of the top 25 drugs most often examined by forensic laboratories in 2011, are available as prescription drugs. (DEA, NFLIS, 2011 mid year report)

BACKGROUND What caused this phenomenon? Prescription drugs do not fall under the clandestine cloud of illegal drugs such as heroin, ecstasy or methamphetamine Drugs are FDA approved Friends and family use them Prescription drugs are more available due to the development of new products and increased sales Drugs are frequently obtained free of cost, over 70 percent of people who abused prescription pain relievers got them from friends or relatives, while approximately 5 percent got them from a drug dealer or from the Internet.* *Results from the 2009 National Survey on Drug Use and Health (NSDUH): National Findings, SAMHSA (2010).

DIVERSION METHODS Doctor shopping or other prescription fraud Illegal online pharmacies Theft and burglary (from residences, pharmacies, etc.) Receiving from friends or family, often for little or no cost Over prescribing (negligent or intentional over prescribing by physicians) Stereotypical drug dealing (selling pills to others)

INFORMATION SOURCES Most abusers do not have technical training and get their information on abuse and extraction methods from friends, publications or the Internet Web sites http://www.courtinfo.ca.gov/opinions/revpub/A100018.DOC http://www.rhodium.ws/chemistry/ http://www.erowid.org/index.shtml http://www.totse.com/en/drugs/speedy_drugs/166004.html http://www.the-hive.ws/forum/forums.pl http://nepenthes.lycaeum.org/Drugs/DXM/extract.html http://www.erowid.org/chemicals/dxm/faq/dxm_chemistry.shtml (good detail) http://www.bluelight.ru/ News group: Alt.drugs, Alt.drugs.hard, Rec.drugs, Lycaeum Amazon.com

INDUSTRY RESPONSE Development of abuse resistant delivery systems Reformulation - Oxycontin Oros® – osmotic pump (POLYOX) Encapsulated pellets Addition of antagonists or aversion ingredients Capsules within capsules Rel-Ease™ - Ionic complexes Packaging Reservoir transdermal patch Pro-drugs ADPREM Dose counting devices Implants Benefit to industry Enhanced corporate image Fewer litigation actions Increased market share Lower schedule ? – more doctors will prescribe Labeling concessions – more doctors will prescribe Perceived as safer – more doctors will prescribe Patient/Public Benefit Reduced abuse and subsequent health care costs

SCHEDULING The DEA in concert with FDA has been delegated the authority to add or transfer substances between schedules if the substance has a potential for abuse and meets the criteria for a particular schedule or they can be completely removed from scheduling Scheduling based on eight factor analysis

EIGHT FACTORS The 8 factors are specified in the Controlled Substance Act (CSA) as: (1) The drug/substance actual or relative potential for abuse (2) Scientific evidence of the drug/substance pharmacological effect, if known (3) The state of current scientific knowledge regarding the drug/substance (4) The drug/substance history and current pattern of abuse (5) The scope, duration, and significance of abuse (6) What, if any, risk there is to the public health (7) The drug/substance psychic or physiological dependence liability (8) Whether the drug/substance is an immediate precursor of a substance already controlled under this subchapter

ABUSE METHODS Physical – oral, snorting, smoking Multiple doses Heating or cutting patches Particle size reduction - Chewing Grinding – hammer, coffee grinder, kitchen utensils Extraction –oral, nasal, smoking, IV Solvent extraction to remove excipients or additatives and/or concentrate active ingredient

DEFINITIONS Tampering – physical manipulation Crushing Physical separation components (beads, layers, gel) Heating, freezing, crisping, microwaving Extractability – chemical manipulation of a product to remove, concentrate and/or purify the active ingredient performed using commonly available equipment and chemicals Procedures may be used individually or in combination – crushing is frequently the first step

IN-VITRO EXPERIMENTS aka KITCHEN CHEMISTRY Every product is different; therefore each requires a unique set of experiments developed under the standardized tests to assess tamperability. Sponsor knows product’s vulnerabilities and should develop experiments in concert with abuse experts based on product knowledge and current abuse methods of similar products using commonly available chemicals and equipment. Standardized laboratory extractions must be developed for each dosage form, e.g. tablets, capsules, patches, liquids, IR, SR using solvents & equipment commonly available. Consider testing all dosage strengths 11

IN-VITRO EXPERIMENTS Develop written protocols that produce statistically valid, reproducible results. Include related comparator product Include controls Include quality assurance procedures All experiments must be conducted at least in triplicate Use graphs and charts to illustrate data Experiments should be conducted by an independent laboratory that is blinded to the fullest extent possible in addition to in house laboratory experiments Take photographs to illustrate results 12

Photos by permission, Egalet, Copenhagen DK, 2010. INJECTABILITY Photos by permission, Egalet, Copenhagen DK, 2010.

PHYSICAL MANIPULATION Particle size reduction is generally the first step. Experiments should be attempted at RT and ET as well as after physical manipulation (heating, freezing, microwaving, crisping) Use a variety of available manual and electric tools Set practical time limits (Egalet study- 80% of subjects would spend 3-10 minutes tampering) Smallest particle size generally produces the most desirable result.

SOLVENT EXTRACTION Solvents of different pH and polarity Soaked and stirred RT and elevated temperature (ET) Ground and intact Percolated Single solvent (ingestible e.g. alcohol, water - non-ingestible e.g. paint thinner, acetone) Multiple solvents - aqueous /pH adjustments & immiscible solvents

ABUSE METHODS All modes of abuse must be considered if relevant Oral – the most commonly encountered Nasal – crushing followed by snorting Smoking – crushing/extracting/smoking – IV – hard core abusers requiring immediate most intense result

EXTRACTABILITY RATING Neither the DEA nor FDA have objective criteria to measure/evaluate extractability, YET. Ideally, a rating system should be developed that would result in a quantitative score that regulators and industry officials could use to determine the relative extractability of any pharmaceutical product. 17

EXTRACTABILITY RATING Objective metrics must be established – Abuser knowledge and skill required Number of steps required Amount and cost of equipment and chemicals Amount of time expended Percent recovery and purity Other active & inactive ingredients recovered Physical characteristics of extract – viscosity, color, odor, syringability

Summary No objective measure exists to measure tamperability/extractability Each product/system requires unique experiments designed to address vunerabilities Use independent laboratory & abuse experts Consider all modes of abuse & all strengths Include photographs, graphs & charts where appropriate No product has been proven to be tamper proof

Thank you Robert P. Bianchi Vice-President and Chief of Scientific and Technical affairs Prescription Drug Research Center 134 N. LaSalle Street Chicago, IL 60602 312-726-8620 - Office 571-233-4780 – Cell RBianchi@pdrcllc.com RBConsulting700@AOL.com